Loading…
← CockpitCompetitor Analysis › 688710.SS Shanghai InnoStar Bio-tech Co. Ltd. Class AOpen in the cockpit ↗

Shanghai InnoStar Bio-tech Co. Ltd. Class A688710.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Shanghai preclinical CRO providing drug-safety and toxicology testing services to Chinese and global pharma developers.

≈ A small Chinese Charles River Labs (toxicology arm)Momentum leader 80
Mkt cap
$1,000M
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$45.6M
20-day average traded
Fwd P/E
59.3×
forward earnings
ROIC−WACC
+3.8 pp
WACC 5.0%
Hurdle
-7 pp
Req g minus delivered
Next earnings
169 days
6 May 2027
Close · CNYCN¥75.86
1D-9.5%
1W-19.3%
1M-11.5%
3M-20.3%
6M+17.3%
YTD+71.8%
1Y+75.6%
ATR %10.1%
52w lowhigh32.3% off high

What Shanghai InnoStar Bio-tech does

Shanghai preclinical CRO providing drug-safety and toxicology testing services to Chinese and global pharma developers.

Is paid per study by drug developers who need toxicology and safety testing before human trials, so revenue follows the number and size of studies it wins, and long-running programmes bring repeat work from the same clients. Laboratories certified to good laboratory practice, the standard regulators require, are its core assets.

In one line: A small Chinese Charles River Labs (toxicology arm).

Products and services

  • Toxicology/safety evaluation studies
  • Other preclinical testing services

Customers

  • Pharma and biotech drug developers

Where it sits in the supply chain

  • Pharma services
  • Contract research
  • Preclinical safety testing

What could go right

  • Rising Chinese drug-development pipeline volume

What could go wrong

  • Biotech funding cycle sensitivity
  • Pricing competition among CROs

Moat: narrow (regulatory licence, installed base). GLP-certified lab facilities and accumulated regulatory track record are slow for new entrants to replicate.

Headquarters: Shanghai, China · Employees: 1,173

Named competitors

Shanghai InnoStar Bio-tech at a glance

Size Shanghai InnoStar Bio-tech (688710.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1,000M, the 2162nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥75.86 on 18 Nov 2026.

Performance Over six months the shares gained 17.3%, against -11.5% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 23.8% over the last twelve months (peer median +7.1%); the operating margin is 6.4% (peer median 12.9%).

Valuation It trades at 59.3× forward earnings against a peer median of 18.3× (2nd most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.8 points above its cost of capital (5.0% WACC).

Next results Next results expected around 6 May 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026688710.SS 115Peer median 91
Six months, rebased to 100: Shanghai InnoStar Bio-tech against the median of its 20 peers (local-currency closes).

Shanghai InnoStar Bio-tech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.03BCN¥811MCN¥1.14BCN¥1.04BCN¥863M
Revenue growth—-29%+10%+20%—
Gross profitCN¥377MCN¥193MCN¥368MCN¥438MCN¥333M
EBITDAn/aCN¥40.7MCN¥211MCN¥269MCN¥186M
Net incomeCN¥78.3M-CN¥30.5MCN¥148MCN¥194MCN¥135M
Free cash flowCN¥207M-CN¥32.6M-CN¥384M-CN¥65.8MCN¥133M
Capital expenditureCN¥179MCN¥134MCN¥288MCN¥234MCN¥146M
Total debtCN¥122MCN¥116MCN¥236MCN¥255MCN¥248M

Quarterly statements and history in the cockpit →

Shanghai InnoStar Bio-tech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%6051166880916005574887000650AARTIPHARM300702688382600129SPTXPGHL30049745656885134553002737688759SVRABSLN688710.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai InnoStar Bio-tech is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×20×40×60×6051166005574887000650300702600129PGHL3004976885134553002737300294BSLN688710.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai InnoStar Bio-tech is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%60511660055700065030070268838230049745654553002737BSLN688710.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai InnoStar Bio-tech is the large dot.

Shanghai InnoStar Bio-tech competitors and peer comparison

Head to head with its named competitors (688710.SS vs CRL vs 2359.HK vs 603127.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shanghai InnoStar Bio-tech 688710.SS$1,000M+17%+24%6%59.3×12.7%
Charles River Laboratories CRL$16.0B+114%-1%15%26.2×25.6%
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%
Joinn Laboratories (China) 603127.SS$3.67B-6%+12%-4%29.4×n/a

How Shanghai InnoStar Bio-tech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai InnoStar Bio-tech against its 20 peers (data as of 18 Nov 2026)
Measure688710.SSPeer medianRank in peer set
1-month return-11.5%-5.0%5th lowest of 21
6-month return+17.3%-11.5%4th highest of 21
Distance from 52-week high-32.3%-32.2%11th highest of 21
Revenue growth (TTM)+23.8%+7.1%5th highest of 18
Operating margin6.4%12.9%6th lowest of 18
Forward P/E59.3×18.3×2nd most expensive of 15
Growth the price implies (Req g, 7 yrs)12.7%3.3%2nd most demanding of 13
Growth delivered (Del g)+19.4%+5.6%2nd highest of 13
Hurdle (Req g minus delivered)-6.7 pp-3.5 pp5th least demanding of 13
ROIC minus cost of capital+3.8 pp-0.2 pp7th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%

Questions

Who are Shanghai InnoStar Bio-tech's main competitors?
Named competitors: Charles River Laboratories (CRL), WuXi AppTec (2359.HK), Joinn Laboratories (603127.SS). The cockpit's measured peer set (industry) also includes Aurisco Pharmaceutical (605116.SS), Shanghai Yizhong Pharmaceutical (688091.SS), Jiangsu Kanion Pharmaceutical (600557.SS), SAWAI (4887.T), Renhe Pharmacy (000650.SZ), Aarti Pharmalabs (AARTIPHARM.NS).
Is Shanghai InnoStar Bio-tech expensive compared with its peers?
On forward p/e it trades at 59.3× against a peer median of 18.3×, 2nd most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Shanghai InnoStar Bio-tech stock performed?
Over six months to 18 Nov 2026 the shares returned +17.3% against -11.5% for the median peer; over one year +75.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.